AstraZeneca has announced positive high-level results from its Phase III POTOMAC trial assessing the efficacy of IMFINZI® ...

The analysis by Ontada tracked testing rates withing the US Oncology Network for PD-L1, FGFR2/3, and HER2 biomarkers over 10 years.

First-line treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) significantly improved survival compared with lenvatinib ...

The approval in MIBC was based on positive results from the phase 3 NIAGARA trial, in which the Imfinzi regimen demonstrated ...

AstraZeneca's Imfinzi, when combined with standard-of-care BCG induction and maintenance therapy, showed DFS improvement.

AstraZeneca (LSE:AZN) recently released positive results from its POTOMAC Phase III trial involving IMFINZI, reflecting ...